Ravi Rao

Dr. Rao joined Oxford Biomedica in March 2022 as Chief Medical Officer. He will be dividing his time between his role at Oxford Biomedica with roles at SV Health Investors and Sitryx. Dr. Rao brings long-standing biopharmaceutical and translation experience from early stage through to launch and life cycle across multiple therapeutic areas with different treatment modalities. Most recently, Dr. Rao was Head of R&D and Chief Medical Officer at Swedish Orphan Biovitrum (Sobi), where he oversaw the development and approval of multiple medicines in rare diseases across immunology and haematology.

Dr. Rao began his biopharmaceutical career at Roche Pharmaceuticals and subsequently held senior positions in R&D at GlaxoSmithKline and as Chief Medical Officer at Aeglea Biotherapeutics. He was previously an academic at Imperial College and a post-doctoral fellow at Harvard University specialising in immunology. Dr. Rao received his medical degree from Cambridge University and his PhD from Imperial College. He is a member of the Royal College of Physicians and a Honorary Member of the Faculty of Pharmaceutical Medicine. He is also an independent board director of DBV Technologies.